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The Telomerase Catalytic Subunit Is a
Widely Expressed Tumor-Associated Antigen
Recognized by Cytotoxic T Lymphocytes
tested one malignancy at a time and, in some cases
(such as the immunoglobulin idiotypic antigen in B cell
malignancies), patient by patient (Rosenberg, 1997). To
circumvent these obstacles, we initiated studies to find
more universal TAA that could trigger CTL responses
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against a broad range of tumor types. Rather than ana-Harvard Medical School
lyzing tumor-derived T cell clones or tumor-specific anti-Boston, Massachusetts 02115
bodies derived from patients, we utilized an alternative³Whitehead Institute for Biomedical Research
strategy in which TAA and their CTL epitopes are de-Cambridge, Massachusetts 02142
duced from genes known to be selectively expressed
in tumors. We hypothesized that the desired antigen
would (1) be expressed by the vast majority of humanSummary
cancers, (2) include peptide sequences that bind to ma-
jor histocompatibility (MHC) molecules, (3) be processedThe discovery of tumor-associated antigens (TAA) in
by tumor cells such that antigen-derived peptides arecertain human malignancies has prompted renewed
available for binding to MHC molecules, (4) be recog-efforts to develop antigen-specific immunotherapy of
nized by the T cell repertoire in an MHC-restricted fash-cancer. However, most TAA described thus far are
ion, and (5) permit the expansion of naive CTL precur-expressed in one or a few tumor types, and, among
sors bearing specific T cell receptors.patients with these types of tumors, TAA expression
The ribonucleoprotein telomerase is expressed byis not universal. Here, we characterize the telomerase
more than 85% of human cancers (Kim et al., 1994), andcatalytic subunit (hTERT) as a widely expressed TAA
therefore we studied whether telomerase might functioncapable of triggering antitumor cytotoxic T lympho-
as a nearly universal TAA. Telomerase maintains thecyte (CTL) responses. More than 85% of human can-
telomeric ends of linear chromosomes, protecting themcers exhibit strong telomerase activity, but normal
from degradation and end-to-end fusion (Greider, 1995).adult tissues, with few exceptions, do not. In a human
Most human cells do not express telomerase (Kim etsystem, CD81 CTL specific for an hTERT peptide and
al., 1994; Meyerson et al., 1997; Nakamura et al., 1997)restricted to MHC HLA-A2 lysed hTERT1 tumors from
and lose telomeric DNA with each cell division (Harleymultiple histologies. These findings identify hTERT as
et al., 1990; Hastie et al., 1990). In contrast, the greata potentially important and widely applicable target
majority of human tumors exhibit strong telomerase ac-for anticancer immunotherapeutic strategies.
tivity (Kim et al., 1994), express hTERT (Meyerson et al.,
1997; Nakamura et al., 1997; Ramakrishnan et al., 1998),
and maintain the length of their telomeres (Counter et al.,Introduction
1992, 1994), suggesting that the activation of telomerase
plays an important role in the development of humanThe scarcity of clinically significant tumor-specific im-
cancers. The telomerase catalytic subunit hTERT is themune responses in cancer patients cast doubt for many
rate-limiting component of the complex, and its expres-years that antigen-specific immunotherapy would play
sion correlates best with telomerase activity (Harrington
a role in clinical oncology. Pioneering studies in the early
et al., 1997; Meyerson et al., 1997; Nakamura et al., 1997;
1990s, however, demonstrated the existence of human
Weinrich et al., 1997; Bodnar et al., 1998; Counter et al.,
TAA using patients' cytotoxic T cells that recognized 1998b; Vaziri and Benchimol, 1998).
peptides derived from these antigens (Van Pel et al., In this study, we identify hTERT-derived peptides that
1995; Rosenberg, 1997). Although these studies primar- bind to HLA-A*0201 (an MHC class I allele expressed
ily focused on melanoma, TAA have been subsequently by nearly 50% of our cancer patients) and report the
characterized in several other malignancies (Van Pel et generation of CTL specific for one such peptide that kill
al., 1995; Rosenberg, 1997; Van den Eynde and van der hTERT1 tumor cells in an MHC-restricted fashion.
Bruggen, 1997), raising the hypothesis that most if not
all tumors express antigens that CTL can potentially Results and Discussion
attack. Consequently, exciting clinical efforts are now
underway to target these TAA in strategies such as vac- The sequence of hTERT was reviewed for peptides that
cination and adoptive T cell therapy in order to generate could potentially bind to HLA class I molecules using a
effective anti-tumor CTL responses in patients (Rosen- peptide-motif scoring system (http://bimas.dcrt.nih.gov/
berg, 1997). molbio/hla_bind/). Starting with the most common HLA
Unfortunately, the expression of most TAA is re- subtype, HLA-A*0201, we identified and tested three
stricted to a few tumor types and to a fraction of patients candidate nonapeptides (Table 1). Each has a unique
with these types of tumors. Clinical studies, therefore, coding sequence within the currently available human
have progressed slowly because strategies have been genome. These peptides were pulsed with b2-micro-
globulin onto the HLA-A*02011 T2 hybridoma in a stan-
dard functional peptide binding assay. Based on in-§ To whom correspondence should be addressed (email: vonder@
mbcrr.harvard.edu). creased expression of HLA-A*0201 on pulsed T2 cells,
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Table 1. Binding of hTERT Peptides and Controls to Human HLA-A*0201
Name Sequence Protein Position Scorea Fluorescence Indexb
I540 ILAKFLHWL hTERT aa540 1746 3.1
E555 ELLRSFFYV hTERT aa555 1670 2.2
R865 RLVDDFLLV hTERT aa865 542 2.2
F271 FLWGPRALV MAGE-3 aa271 2655 2.7
(positive control)
I540-S HFLLWKLIA hTERT scrambled 0 0.2
(negative control)
A98-Idc AHTKDGFNF Idiotype aa98 0 0.0
(negative control)
a Calculated score in arbitrary units.
b (Mean fluorescence with peptide 2 mean fluorescence without peptide)/(mean fluorescence without peptide). Results representative of two
experiments.
c Peptide sequence obtained from the idiotypic sequence of a patient with plasma cell leukemia and predicted to bind to HLA-B38.
each peptide was found to bind strongly to HLA-A*0201 generated from two donors with the MAGE-3 peptide
also failed to lyse U2OS-TERT cells or U2OS-pB cells(Table 1). A positive control peptide derived from the
tumor antigen MAGE-3 also bound strongly, but two (Figure 2A); however, these CTL killed the HLA-A*0201
MAGE-3-positive melanoma cell line K029 (.30% spe-negative control peptides did not. The MAGE-3 peptide
(F271) has been previously identified by a similar predic- cific lysis at an E:T ratio of 30:1 for each line) (data not
shown).tion analysis to bind to HLA-A*0201 (van der Bruggen
et al., 1994). Induction of F271-specific CTL can lead to Our findings suggest that the I540 hTERT peptide ful-
fills the requirements for a TAA capable of triggeringlysis of MAGE-3-positive tumor cells (van der Bruggen
et al., 1994; Fujie et al., 1997). In addition, a soluble CTL responses: it can be naturally processed by tumor
cells, presented in an MHC-restricted fashion, and per-polyvalent melanoma antigen vaccine that includes the
MAGE-3-derived F271 peptide has been prepared from mits expansion of hTERT-specific CTL. To test whether
I540-specific CTL can recognize this antigen in a broadmaterial shed into culture medium by four melanoma
lines (Bystryn et al., 1992) and can trigger F271-specific range of tumors, cytotoxicity was evaluated against a
panel of tumor cells with diverse histologic origins. EachCTL in vivo (Reynolds et al., 1997).
We then generated CD31CD81 CTL specific for the tumor cell type expressed nearly equal amounts of sur-
face MHC class I, as determined by flow cytometry (datahTERT peptides and tested them for their ability to kill
tumor cells in an hTERT-dependent fashion. CTL were not shown). Expression of the HLA-A*0201 allele was
evaluated by flow cytometry and PCR. Telomerase activitygenerated from CD81 T cells from the peripheral blood
of normal HLA-A*0201 donors by priming with peptide- was observed in all tumors except one melanoma cell line
(Figure 3A). As shown in Figure 3B, I540-specific CTLpulsed autologous dendritic cells (DC) followed by
weekly restimulation with autologous CD40-activated B lysed an HLA-A*02011 carcinoma line but not an HLA-
A*0201-negative carcinoma line. MAGE-3-specific CTLcells (Schultze et al., 1997). After three restimulations,
.88% of cells in each culture were CD31 lymphocytes, did not lyse either carcinoma line (data not shown). Simi-
larly, I540-specific CTL lysed two HLA-A*02011 multipleof which .88% were CD81 and 0.3%-3.6% were CD41.
Cultures were ,0.4% CD141 and 3.0%-3.9% CD561. myeloma cell lines but not an HLA-A*0201-negative my-
eloma line (Figure 3C). I540-specific CTL also lysed anTo create target cells in which hTERT was processed
naturally, we used amphotropic retroviruses to infect HLA-A*02011 malignant melanoma line but not an HLA-
A*0201-negative melanoma line that lacked telomerasethe hTERT-negative, HLA-A*02011 osteosarcoma line
U2OS with either a vector encoding the full sequence activity (Figure 3D). Finally, we tested I540-specific CTL
against Epstein Barr virus (EBV)±transformed B cell linesof hTERT (U2OS-TERT cells) or with a virus specifying
only a drug-resistance marker (U2OS-pB cells). The re- as a model of EBV-related lymphoproliferative disor-
ders. Each of these lines expressed HLA-A*0201, butsulting polyclonal population (U2OS-TERT) expressed
hTERT and demonstrated telomerase activity whereas only one line had telomerase activity (Figure 3A). I540-
specific CTL lysed the telomerase-positive but not thethe vector control population (U2OS-pB) did not (Figure
1). U2OS-TERT and U2OS-pB cells expressed similar telomerase-negative line (Figure 3E), further demon-
strating antigen specificity of the cytotoxic response.levels of HLA-A*0201 and CD58 and lacked MHC class
II, CD54, and CD80 (data not shown). CTL generated To investigate the possibility that I540-specific cyto-
toxicity was restricted to immortalized cell lines, we thenfrom five of seven donors with the hTERT peptide I540
lysed U2OS-TERT cells but not the control U2OS-pB studied CTL lysis of freshly isolated, primary tumor cells.
Acute myelogenous leukemia (AML) cells were obtainedcells (Figure 2A), demonstrating specificity for hTERT.
Consistent with HLA-restricted cytotoxicity, I540-spe- by bone marrow aspiration from an HLA-A*0201 patient
at the time of clinical presentation, and non-Hodgkin'scific lysis of U2OS-TERT cells was significantly blocked
by anti-MHC class I mAb but not control mAb (Figure lymphoma (NHL) cells from two patients were obtained
after biopsy of markedly involved lymph nodes. One2B). T cell lines generated with the other candidate
hTERT peptides (two donors) did not lyse U2OS-TERT NHL patient expressed HLA-A*0201 (patient 1) whereas
the other patient was HLA-A*0201-negative but MHCcells or U2OS-pB cells (data not shown). T cell lines
Targeting Telomerase as a Tumor-Associated Antigen
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Figure 2. hTERT-Specific, HLA-Restricted Lysis of Infected U2OS
Osteosarcoma Cells
(A) U2OS-TERT cells (squares) and U2OS-pB cells (circles) were
used as targets for I540 CTL (solid symbols) or F271 MAGE-3 CTL
(open symbols). Results (mean 6 SD) of one representative experi-
ment of three performed using an individual line are shown. Similar
results were obtained for I540 CTL generated from four other donors
and for F271 CTL from one other donor. I540 CTL killed only U2OS-
TERT cells whereas F271 CTL killed neither target.
(B) I540-specific cytotoxicity against U2OS-TERT cells was tested
at an effector:target ratio of 30:1. Lysis of U2OS-TERT cells by I540-
specific CTL could be inhibited by anti-HLA-A2 mAb BB7.2 but not
with media or the anti-B5 control mAb.
CTL were generated (including one pair from the same
donor) and were directly compared. Over a range of
E:T ratios, I540-specific and F271-specific cytotoxicity
against K029 was similar (e.g., 46.1% versus 32.0%,
Figure 1. hTERT Expression Confers Telomerase Activity in U2OS respectively, for one pair of CTL, and 87.0% versus
Osteosarcoma Cells 64.7% for a second pair of CTL generated from the
(A) Telomerase-negative U2OS cells were infected with pBabe-puro same donor, tested at an E:T ratio of 30:1). Although
or pBabe-puro-hTERT. Expression of hTERT mRNA was evaluated this finding suggests that CTLs recognizing I540 and
by an RNase protection assay. Input antisense probes are shown
F271 have similar cytotoxic efficiencies for tumor cellson the left. The RNase-resistant, protected fragments representing
expressing these antigens, we are currently generatinghTERT and human b-actin are shown on the right.
a panel of T cell clones from healthy donors and cancer(B) Cytosolic cellular extracts (0.2 or 0.02 mg) prepared from the
vector- or hTERT-infected cells were assayed for telomerase activity patients to answer this question definitively.
by telomeric repeat amplification protocol (TRAP). A 36 base pair Because most human cancers have high levels of telo-
internal control PCR product (IC) was seen for each reaction. As a merase activity, immunotherapeutic strategies aimed at
negative control, 2 mg of each extract was heat treated (HT) to
this antigen may have broad clinical applications. Theinactivate telomerase.
major concern of such an approach would be cytolysis
of the few normal cell types in which telomerase can be
detected. Telomerase activity has not been detected inclass I±positive (patient 2). Each primary tumor tested
was telomerase-positive (Figure 4A). As shown in Figure adult cardiac, renal, hepatic, pulmonary, neural, skeletal,
and adipose tissues; however, hematopoietic stem cells4B, I540-specific CTL lysed the HLA-A*02011 AML and
NHL cells but not the HLA-A*0201-negative NHL cells. and progenitors, germinal center cells, basal keratino-
cytes, gonadal cells, and certain proliferating epithelialThese results demonstrate that in a range of primary
tumors and transformed cell lines, endogenous hTERT cells have been reported to have measurable telomerase
activity (Harle-Bachor and Boukamp, 1996; Yasumotois naturally processed, presented in the context of HLA-
A*0201, and serves as a target for antigen-specific CTL. et al., 1996; Norrback and Roos, 1997; Kolquist et al.,
1998). We therefore examined I540-specific CTL lysis ofTo evaluate the relative efficiency of I540 recognition
by the CTL populations tested and hence to assess the normal cells, starting with peripheral blood CD341 cells
as important potential targets. CD34-enriched cells fromsignificance of the level of cytotoxicity obtained against
telomerase-positive cells, we compared cytotoxicity of two patients (patient 3, HLA-A*02011 and 45% CD341
CD451; patient 4, HLA-A*02012 but class I1 and 76%I540 CTL with MAGE-3 F271 CTL against the same tar-
get. The K029 melanoma cell line was used as the target CD341CD451) were used as targets. Although CD34-
enriched cells had telomerase activity (Figure 5A), nobecause it endogenously expresses both hTERT and
MAGE-3. Two pairs of I540-specific and F271-specific lysis by I540-specific CTL was observed (Figure 5B),
Immunity
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Figure 3. I540-Specific CTL Lyse Tumor Cells
from Multiple Histologic Origins in an HLA-
A*0201-Restricted Fashion
(A) Targets were evaluated for telomerase ac-
tivity and HLA class I expression. Extract dilu-
tions were used to evaluate the presence of
TRAP inhibitors. The optimal amount of ex-
tract was then used as follows: 293, 30 ng;
Calu-1, B4, K029, and K017, 1 mg; and for
each other cell line, 200 ng. The TRAP internal
control (IC) is shown for each extract. I540-
specific CTL were tested for cytotoxicity
against (B) carcinoma, (C) multiple myeloma,
(D) malignant melanoma, and (E) EBV-trans-
formed B cell lines. Lysis of U2OS-TERT cells
is also shown for comparison. HLA-A*0201
(A2) and telomerase (Tel) phenotypes are
summarized for each target. Results (mean 6
SD) of one representative experiment of two
performed using an individual line are shown.
Similar results were obtained for each of three
other I540 CTL tested. I540-specific CTL
lysed targets of each histologic type in an
HLA-A*0201-restricted and telomerase-depen-
dent fashion.
suggesting that hTERT does not readily function as an therefore examined the ability of I540-specific CTL to
lyse professional antigen-presenting cells in which anyautoantigen on hematopoietic precursor cells. However,
CD341 cells from patient 3 could be lysed by I540-spe- such defect would be less likely. Autologous DC pre-
pared from peripheral blood lacked telomerase activitycific CTL if initially pulsed with I540 peptide but not if
pulsed with F271 MAGE-3 peptide (data not shown). and were not lysed by I540-specific CTL (Figure 5). Rest-
ing peripheral B cells also lack telomerase activity, butThese findings may reflect low hTERT expression in
CD34-enriched cells that is still detectable by the PCR- after prolonged stimulation in vitro with CD40 ligand,
these B cells have telomerase activity (Figure 5A). CD40-based telomerase assay; however, this assay cannot
be used to delineate quantitative differences in hTERT activated B cells function well as antigen-presenting
cells (Schultze et al., 1997) and parallel germinal centerexpression between cell types, although qualitative dif-
ferences such as positive versus negative signals are B cells in many ways including their telomerase activity.
As shown in Figure 5B, autologous CD40-activated Bmeaningful (Prowse and Greider, 1995). Alternatively,
assuming that the level of hTERT expression in stem cells were lysed by I540-specific CTL. Therefore, it is
possible that hTERT-specific CTL could, if given thera-cells and progenitors is not in fact rate-limiting for CTL
activation, these cells may not be able to process this peutically, kill germinal center B cells and other acti-
vated B cells, potentially jeopardizing the in vivo role ofantigen and present it in the groove of MHC class I. We
Targeting Telomerase as a Tumor-Associated Antigen
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Figure 5. Evaluation of Telomerase Activity and I540-Specific CTL
Cytotoxicity of Normal Cells
(A) Telomerase activity is shown for U2OS-TERT cells, CD34-enriched
peripheral blood cells from two patients, CD40-activated B cells,
DC, and two types of primary keratinocytes. For U2OS-TERT cells,
Figure 4. Evaluation of I540-Specific CTL Cytotoxicity against Pri-
300 or 100 ng of cytosolic extract was used; for the other cells, 1
mary Tumor Cells
mg or 300 ng was used. As a negative control, 2 mg of each extract
(A) Telomerase activity is shown for U2OS-TERT cells, NHL cells was heat treated (HT) to inactivate telomerase prior to assay. The
from two patients, and AML cells from one patient. For all cells, 300 TRAP internal control (IC) is shown for each reaction. U2OS-TERT
or 30 ng of cytosolic extract was used. As a negative control, 2 mg cells, CD34-enriched cells, and CD40-activated B cells had telo-
of each extract was heat treated (HT) to inactivate telomerase prior merase activity, but DC and keratinocytes did not.
to assay. The TRAP internal control (IC) is shown for each reaction. (B) I540-specific CTL were tested for cytotoxicity against CD34-
(B) I540-specific CTL were tested for cytotoxicity against NHL and enriched cells, autologous DC, and autologous CD40-activated B
AML cells. Lysis of U2OS-TERT cells is also shown for comparison. cells. Lysis of U2OS-TERT cells is also shown for comparison. Re-
Results (mean 6 SD) of one experiment are shown. I540-specific sults (mean 6 SD) of one representative experiment of two per-
CTL lysed each primary tumor target except NHL cells from the formed using one line are shown. Although I540-specific CTL lysed
patient negative for HLA-A*0201. U2OS-TERT cells and CD40-activated B cells, no lysis was observed
against DC or CD34-enriched cells.
B cells to present antigen during an immune response.
However, our observation that DC lack telomerase ac- time-sensitive, trypsin fractionation protocol from whole
epidermis. This protocol produced enough cells to per-tivity suggests that DC could maintain primary anti-
gen-specific T cell activation even in the face of I540- form the PCR-based TRAP assay but insufficient to per-
form chromium-release assays. Likewise, we have beenspecific CTL.
In an attempt to test whether other normal telomerase- unable to establish a primary epithelial cell culture that
expresses endogenous telomerase. Consequently, ex-positive cells are susceptible to hTERT-specific lysis, we
obtained freshly isolated human foreskin keratinocytes tensive in vitro evaluation as to whether hTERT-specific
CTL would lyse normal telomerase-positive cells willand human oral keratinocytes and tested them for telo-
merase activity. Consistent with other reports (Klingel- require the ability to first obtain such cells in sufficient
quantity for the appropriate assays. Clinical attempts tohutz et al., 1994, 1996; Stoppler et al., 1997; Kiyono et al.,
1998), we did not find that freshly isolated keratinocytes target hTERT as a tumor antigen in cancer patients will
also offer major insights into this question.express detectable telomerase activity (Figure 5A). In a
report that identifies telomerase-positive keratinocytes Potential tumor cell resistance to TAA-specific CTL
represents another concern in the development of thera-(Harle-Bachor and Boukamp, 1996), the authors were
only able to isolate telomerase-positive cells through a peutic strategies based on the I540 hTERT peptide.
Immunity
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(Counter et al., 1998b) and telomeric repeat amplification protocolSome tumors lack telomerase activity and may maintain
(TRAP) assays (Kim and Wu, 1997) were performed as described.telomere length by an alternative mechanism (Bryan et
al., 1997). The possibility, therefore, of selecting I540-
Generation of CTLnegative or telomerase-negative tumor clones in vivo
DC were prepared using IL-4 and GM-CSF as described (Schultze
must be considered. et al., 1997) with .80% of cells CD831 CD142. B cells were activated
In summary, we demonstrate that a peptide derived and cultured via CD40 as described (Schultze et al., 1997) with
from the telomerase catalytic subunit can be naturally .80% CD191 CD32. CD8-enriched T cells (.89% CD81, .95%
CD31, ,0.5% CD41, and ,5% CD561) were prepared as describedprocessed by tumor cells, presented in an HLA-A*0201-
(Schultze et al., 1997). DC were harvested after 7 days in culture,restricted fashion, and serve as a target for antigen-
pulsed with peptide (40 mg/ml) and b2-microglobulin (3 mg/ml) forspecific CTL. Cytotoxicity was achieved against target
4 hr at 378C, irradiated (33 Gy), and added to autologous CD8-
cells from a wide variety of histologic origins including enriched T cells at a T:DC ratio of 20:1 in RPMI media with 10%
carcinoma, sarcoma, multiple myeloma, malignant mel- human AB serum, 2 mM glutamine, 15 mg/ml gentamicin, 20 mM
anoma, acute leukemia, non-Hodgkin's lymphoma, and HEPES, and 10 ng/ml IL-7 (Sigma). At day 7 and weekly thereafter,
T cell cultures were harvested and restimulated with irradiated (33EBV-transformed B cells. These findings together with
Gy), peptide-pulsed autologous CD40-activated B cells as de-the identification of telomerase activity in the vast major-
scribed (Schultze et al., 1997). IL-2 (50 U/ml; Collaborative Bio-ity of human cancers suggest that hTERT represents
medical Products) was introduced on day 8 and replenished asthe most widely expressed TAA yet described. Impor- needed every 3±4 days. Flow cytometry was performed as described
tantly, in considering hTERT-specific cytolysis of normal (Schultze et al., 1997). The I540 hTERT peptide was tested in seven
cells, we did not observe cytotoxicity against CD341 donors, and the other hTERT peptides and the F271 MAGE-3 peptide
were tested in two donors.(telomerase-positive) peripheral blood cells. Given the
prevalence of the HLA allele studied here, nearly 50%
Cytotoxicity Assayof cancer patients could potentially be considered for
CTL as effector cells were used after the third or fourth restimulation.immunotherapeutic strategies targeting this hTERT pep-
Cr51-labeled targets were used in standard 4 hr Cr51-release assaystide. The number of patients would be further increased
performed in triplicate per condition using 5 3 103 labeled target
with the identification of additional hTERT peptides that cells per well in a 96-well plate. Percent specific lysis was calculated
bind to other HLA alleles, as seems likely based on our from cpm of (experimental result 2 spontaneous release)/(maximum
preliminary review of other HLA-binding motifs within release 2 spontaneous release).
the hTERT sequence. The wide applicability of hTERT
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